Abstract 2200P
Background
Mediastinal neoplasms are typical but uncommon thoracic diseases with increasing incidence and unfavorable prognoses. A comprehensive understanding of their spatiotemporal distribution is essential for accurate diagnosis and timely treatment. However, previous studies are limited in scale and data coverage. Therefore, we delineate the distribution of mediastinal lesions within a substantial, nationwide, multi-institutional cohort, thereby providing valuable insights into this disease.
Methods
In this multi-center, hospital-based, observational study, we included 20 hospitals from 11 provinces in China. At each institution, a standardized retrospective search of electronic medical records between Jan. 1st, 2009 and Dec. 31st, 2020 was performed. We collected information on sociodemographic characteristics, CT images, and pathologic diagnoses. The incidence of mediastinal neoplasms was analyzed in terms of age, sex, time, compartment, and geographical region.
Results
Among 7,829 cases, the most common mediastinal lesions were thymomas (30.6%), benign mediastinal cysts (23.3%), and neurogenic tumors (10.0%). The distribution of these lesions varied significantly among mediastinal compartments, with thymomas (39.6%), benign cysts (28.0%), and neurogenic tumors (51.7%) being the most commonly observed lesions in the prevascular, visceral, and paravertebral mediastinum, respectively (P < 0.001). The occurrence of mediastinal lesions varied by age, with germ cell tumors being more frequently observed in patients younger than 18 and those aged 18-29 years, whereas thymomas occurred more often in patients over 30 (P < 0.001). Also, the lesion location was associated with age, with patients having paravertebral lesions being the youngest (P < 0.001). Spatial distribution analysis revealed that thymomas were the most common mediastinal lesions across different geographical regions.
Conclusions
This study revealed significant heterogeneity in the spatiotemporal distribution of mediastinal neoplasms. These findings provide useful demographic data when considering the differential diagnosis of mediastinal lesions, and would be beneficial for tailoring disease prevention and control strategies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2150P - Clinical and molecular characterisation of cancer-associated venous thromboembolism (VTE)
Presenter: Pau Mascaró Baselga
Session: Poster session 07
2151P - Incidence patterns and clinical implications of venous thromboembolism (VTE) in patients (pts) with neuroendocrine tumors (NET)
Presenter: Jorge Hernando
Session: Poster session 07
2152P - Prognostic importance of GRIM score on sorafenib side effects, hospitalization and survival in hepatocellular cancer patients
Presenter: Duygu Ercan Uzundal
Session: Poster session 07
2153P - Circulating biomarkers to predict severe complications in cancer patients with low-risk chemotherapy-associated febrile neutropenia
Presenter: Sofía Wikström Fernandez
Session: Poster session 07
2154P - Total cholesterol as an independent prognostic factor in cancer patient survival: A single institution experience
Presenter: Maria Alameda-Guijarro
Session: Poster session 07
2156P - Use of taxanes during pregnancy: A systematic review
Presenter: Ana Ferrigno Guajardo
Session: Poster session 07
2157P - A phase II randomised controlled trial comparing the cardiotoxicity of capecitabine and S-1
Presenter: Sally Clive
Session: Poster session 07
2158P - A self-assessment survey to identify the risk of patient’s screen fail in phase I clinical trials (SCITEP trial)
Presenter: Kaissa Ouali
Session: Poster session 07
2159P - Machine learning algorithms to predict the risk of chemotherapy-related toxicity in older Asians
Presenter: Mingwei Li
Session: Poster session 07
2160P - Sociodemographic disparities associated with financial toxicity in stage IV non-small cell lung cancer survivors
Presenter: Mitchell Parma
Session: Poster session 07